Alembic Pharmaceuticals Ltd has secured final approval from the USFDA for its generic Diltiazem Hydrochloride extended-release capsules. These capsules, available in strengths of 120 mg to 360 mg, are designed to treat hypertension and manage angina. This approval grants Alembic access to an estimated market valued at USD 105.3 million annually. Read The Rest at :
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.
